Company: LHI
Filing Date: 2025-09-29
Form Type: F-1/A
Source: 0001213900-25-092499
Chunk: 35

Company: Living Homeopathy International Ltd.
Filing Date: 2025-09-29
Form: F-1/A
Chunk 35
---
 to the PRC Advertising Law, which will result in monetary penalties. See “Regulation – Regulations Related to our Business Operation in Mainland China” on page 92 of this prospectus for more details.

If we fail to adapt to any new regulatory requirement of our existing markets or the regulatory requirements of new regions where we sell our products, or any competent government authority considers that we operate our business without any requisite license, permit or approval, or otherwise fails to comply with applicable regulatory requirements, we may be subject to administrative actions and penalties against us, including fines, confiscation of our incomes, revocation of our licenses or permits, or, in severe cases, cessation of certain business. Any of these actions may have a material and adverse effect on our business, financial condition and results of operations.

<div align='center'>18</div>

Potential product liability, false marketing or other consumer claims against us could cause us to incur substantial liabilities and we may face regulatory penalties.

Our homeopathic remedies, homeopathic co-remedies
and classical flower remedies are for human use. We may face the risk of product liability claims and other consumer claims that are
inherent in sales of products for human consumption. To ensure product safety, our quality control procedure comprises manufacturer selection
and product quality check. For example, in 2023, we have adopted the quality control practice of requesting our suppliers of homeopathic
co-remedies supplier to provide certificate of hygiene or bacteria check, certificate of the origin, and certificate of free sale, as
applicable. In addition, in 2023, we have adopted the quality control practice of sending samples of existing products to HK STC approximately
once or twice a year and sending samples of new products for testing at Hong Kong STC prior to making any sales. See “Business – Quality Control” on page 82 of this prospectus for further details. Despite the quality control practice, if any of
the products we sell are believed to cause injury, not safe or cause an adverse effect. We may face the risk of product liability, which
could adversely affect our business, financial condition and results of operations. Product liability might be brought against us by
regulators, consumers, or others coming into contact with our products. As of the date of this prospectus, we are not aware of any product
liability claim against us. However, if any human consumption of our products results in any harmful side effective, consumers may bring
legal actions against us for damages and regulators